- Home
- PLX vs ARQQ Comparison
PLX vs ARQQ Comparison
Compare PLX & ARQQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- ARQQ
- Stock Information
- Founded
- PLX 1993
- ARQQ 2017
- Country
- PLX Israel
- ARQQ United Kingdom
- Employees
- PLX N/A
- ARQQ N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- ARQQ Computer Software: Prepackaged Software
- Sector
- PLX Health Care
- ARQQ Technology
- Exchange
- PLX Nasdaq
- ARQQ Nasdaq
- Market Cap
- PLX 160.2M
- ARQQ 173.1M
- IPO Year
- PLX 1998
- ARQQ N/A
- Fundamental
- Price
- PLX $2.59
- ARQQ $13.86
- Analyst Decision
- PLX Strong Buy
- ARQQ Strong Buy
- Analyst Count
- PLX 1
- ARQQ 1
- Target Price
- PLX $15.00
- ARQQ $52.00
- AVG Volume (30 Days)
- PLX 764.3K
- ARQQ 548.2K
- Earning Date
- PLX 03-17-2025
- ARQQ 05-19-2025
- Dividend Yield
- PLX N/A
- ARQQ N/A
- EPS Growth
- PLX N/A
- ARQQ N/A
- EPS
- PLX 0.04
- ARQQ N/A
- Revenue
- PLX $53,399,000.00
- ARQQ $293,000.00
- Revenue This Year
- PLX $67.17
- ARQQ $1,818.77
- Revenue Next Year
- PLX $55.31
- ARQQ N/A
- P/E Ratio
- PLX $71.07
- ARQQ N/A
- Revenue Growth
- PLX N/A
- ARQQ N/A
- 52 Week Low
- PLX $0.82
- ARQQ $3.72
- 52 Week High
- PLX $2.76
- ARQQ $52.79
- Technical
- Relative Strength Index (RSI)
- PLX 58.97
- ARQQ 42.84
- Support Level
- PLX $2.43
- ARQQ $16.50
- Resistance Level
- PLX $2.62
- ARQQ $20.70
- Average True Range (ATR)
- PLX 0.14
- ARQQ 2.46
- MACD
- PLX 0.02
- ARQQ -0.27
- Stochastic Oscillator
- PLX 85.00
- ARQQ 6.70
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About ARQQ Arqit Quantum Inc.
Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology that makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. The company delivers its symmetric key agreement technology via its product QuantumCloud. The firm operates in one segment that is, the provision of cybersecurity services via satellite and terrestrial platforms. The company operates and generates its revenue from UK.